SWFMenu Placeholder.

News and Updates

Q4-2012.  gmsbiotech is pleased to announce that Mr. Milan Patel has joined as CFO & Alan Jernigan as SVP of Sales & Marketing. Prior to joining GMSBiotech Mr. Patel served as Chief Financial Officer of 2020 Company, LLC- a leading professional services firm that delivered business and technology solutions to the government, in the areas of health, education and science.  Alan Jernigan has held previous senior level positions in prestigious companies such as One Lambda, a leader in Transplant Diagnostics, where he was their Chief Marketing Officer.

gmsbiotech has secured private funding to accelerate HLA Product Launch and FDA 510(k) submission.

gmsbiotech has received Letter of Certification as a Qualified Small Business for the Small Business Capital Investment Incentive Program from Arizona Commerce Authority.


May 2012. gmsbiotech received a US patent (No. 8,183,360) on Population Scale HLA-Typing and Uses Thereof on May 22, 2012.

Dr. Krishna Jayaraman President & CEO was invited to make a presentation and to be a panel member in the 14th Annual SBIR/STTR Conference held in Louisville, Kentucky (May 30th-June 1st)

April 2012. gmsbioetch received a two year R21grant from National Heart Blood and Lung Institute for High-Throughput HLA-Typing: on Raw, Unpurified Cord Blood Samples. gmsbiotech will have access to archived cord blood samples from NHLBI.

An article on this grant award appeared in Genomeweb News (May 10, 2012)

October 2011. gmsbiotech made a poster presentation at the 37th Annual Meeting of ASHI held in New Orleans from October 17th -21st. The title of the presentation was ”High-Throughput HLA Typing Via Touch Rehydration of Dried Blood On Guthrie Cards”.

September 2011. Dr. Nutan Dighe, Senior Scientist from Bangalore Medical Services Trust, India underwent a two week comprehensive training in advanced HLA Chip Technology at gmsbiotech Tucson facility.

August 2011. gmsbiotech was awarded a Phase I SBIR grant by National Heart, Blood and Lung Institute (NHBLI) titled "The transfusion chip: a simple, low cost microarray for DNA-based blood typing." The grant was awarded on Aug 1 and is set to expire on Jan. 30, 2012.

The grant will help gmsbiotech develop an array-based blood-screening device that could replace existing serological techniques used in blood banks.

June 2011. gmsbiotech will present at Cambridge Healthtech Institute’s The Business of Genomics: Planning to Survive and Thrive as part of the upcoming Beyond Sequencing meeting, on June 20th 2011 in San Francisco.

gmsbiotech will present at the 13th Annual NIH SBIR/STTR Conference organized by NIH on June 22, 2011. gmsbiotech is one of among over fifty NIH SBIR and/or STTR Phase II awardees that will display their scientific findings at the meeting.

May 2011.
gmsbiotech launched alpha testing of its HLA Chip technology in the ASHI-certified Histocompatibility and Transplant Immunology laboratories of The Methodist Hospital, Houston TX, under the direction of Dr. Geoffrey Land. Dr. Land is the current President of ASHI.


gmsbiotech is listed in the NIH “Success Story” website. See under Genomics USA at
http://grants1.nih.gov/grants/funding/sbir_successes/sbir_successes.htm. The companies listed in this website have used the SBIR/STTR funding to successfully commercialize their products. Past inclusion in this website in the life science category includes companies such as Illumina and NimbleGen.

April 2011.
Jennifer Morgan, Ph.D., Senior Scientist from the New Zealand Blood Services Labs completed a comprehensive 1-week training session at gmsbiotech labs in Tucson: comprising advanced training in HLA-Chip technology and Ricimer analysis tools.

January 2011. gmsbiotech has expanded its R&D facility with the addition of another 2000 sq. ft.of laboratory space.

November 10, 2010. Dr. Michael Hogan, The Chief Scientific Officer of gmsbiotech, will be presenting a talk at the APHIA (Asia-Pacific Histocompatibility & Immunogenetics Association) to be held in Queenstown, New Zealand from 16-19 November 2010 titled“Microarray-Based HLA Typing on Unpurified Samples from Blood and Buccal Swabs”.

gmsbiotech  received notification of grant award from the IRS for the Qualified Therapeutic Discovery Project for the development of a microarray based HLA typing technology for solid organ and marrow transplantations and as a diagnostic tool in the personalized medicine applications.

Sepember 27, 2010. gmsbiotech to present a talk and a poster at the annual meeting of the American Society for Histocompatibility and Immunogentics (ASHI) in Hollywood Florida (Sept 26-30th) entitled: “Microarray-Based HLA Typing on Unpurifed DNA Samples from Blood and Buccal Swabs”. This is the first discussion of a new gmsbiotech technology, to perform low cost HLA typing on raw blood, dried blood spots and from cheek swabs,in a way that bypasses DNA purification.

August 1, 2010.
gmsbiotech launched alpha testing of its HLA Chip technology in the ASHI-certified laboratories of The New Zealand Blood Labs, Auckland NZ, under the direction of Dr Paul Dunn. This alpha test program will be used to validate the technology, for low cost HLA typing in the context of routine workflow in an ASHI-certified tissue typing laboratory.

July 1, 2010.gmsbiotech will conduct its business (DBA) in the name of gmsbiotech (Genetics Made Simple) to reflect the simplifications inherent in its technologies for complex, population-scale genetics.

February 23, 2010.
The US Patent and Trademark Office has awarded gmsbiotech a patent: Hogan ME, Jayaraman K, Mitra R & Eggers RH. Population Scale HLA Typing and Methods Thereof. US Patent No. 7,667,026. This US patent confirms broad protection to the design of its HLA-Chip products.

November 3, 2009.gmsbiotech presented its HLA-Chip technology at the 35th annual meeting of The American Society of Histocompatibility and Immunogenetics (ASHI). This appearance was a springboard event for gmsbiotech to obtain ASHI certification of its HLA-Chip technology. The HLA-Chip product consists of gene probes for the analysis of genetic compatibility in marrow, stem cell& solid organ transplantation: the well-known backbone of transplantation medicine.

August 15, 2009.
The National Institute of Allergy and Infectious Disease has awarded a three year, Phase II SBIR Competitive Continuation grant to gmsbiotech, to support ASHI & FDA approval of its "HLA-Chip" Product for low cost, population-scale HLA-typing. This Phase II Continuation Grant award is significant, in that such programs must have already completed a successful Phase II, and the resulting product must stand ready, during the three-year Continuation Phase, for validation and approval by a Federal regulatory agency such as the FDA.

August 15, 2009.
The National Institute of Allergy and Infectious Disease has awarded a two year, Phase I Advanced Technology SBIR grant to gmsbiotech, to support development of an "AIDS-Chip" to be used for population scale analysis of the personalized risk of HIV infection and personalized response to AIDS therapy, based on variation in the human immune system. This product development program is an important milestone for gmsbiotech, in that it parallels the company's move into the personalized genetic medicine of vaccines and chemical therapeutics.

July 2009.
Dr. Kamala Balakrishnan has joined the company as an Advisor
Q3-2008. gmsbiotech received a Notice of Intent to grant the European patent application No. 02748133.2 titled “Methods and Devices Based Upon A Novel Form of Nucleic Acid Duplex On A Surface”.

Q3-2008.
Dr. Paul Dunn, Director of HLA typing lab of NewZealand Blood Services, Auckland, has joined the gmsbiotech team as ASHI Director and HLA Advisor.

April 8, 2008.
The US Patent and Trademark Office has awarded to gmsbiotech, the US Patent 7,354,710, "Methods and devices based upon a novel form of the nucleic acid duplex on a surface". This patent comprises an important base for the gmsbiotech technology platform.

Q3-2006.
gmsbiotech receives funding of about $3 million for 3 years effective from September 1, 2006 for its Phase 2 grant "Population-scale HLA typing for home land defense.

Q2-2006.
gmsbiotech receives funding from QuantRx BioMedical Corporation.

Q2-2004.
gmsbiotech’s SBIR Phase I grant "Population-scale HLA typing for home land defense," is funded by NIAID, effective May 1, 2004. for $498,500.

Q3-2003.
gmsbiotech is awarded a seed grant from Chicago ITEC to continue its feasibility studies.






Terms and Conditions   Site Map     Copyright 2010 gmsbiotech. All rights reserved.  Website by Fort Support   
p news updates